BioInvent International AB (publ) (STO: BINV)

Market Cap	3.00B
Revenue (ttm)	38.64M
Net Income (ttm)	-409.65M
Shares Out	65.80M
EPS (ttm)	-6.22
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	126,185
Open	47.50
Previous Close	47.50
Day's Range	44.05 - 47.60
52-Week Range	14.44 - 50.80
Beta	0.33
Analysts	n/a
Price Target	n/a
Earnings Date	Oct 31, 2024

About BINV

BioInvent International AB (publ), a clinical-stage company, discovers, researches, and develops novel immuno-modulatory antibodies for the treatment of cancer in Sweden, Europe, the United States, and internationally. Its drug candidates are BI-1808 is in phase 2 clinical trial and BI-1910 in phase 1 clinical trial for solid tumors targeting Tumor necrosis factor receptor-2 (TNFR2); BI-1206/rituximab in phase 2 clinical trial for the treatment of non-Hodgkin’s lymphoma; BI-1206/pembrolizumab and BI-1607/trastuzumab in phase 1 clinical trial to...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1996
• Employees: 111
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: BINV

Financial Performance

In 2023, BINV's revenue was 71.46 million, a decrease of -78.09% compared to the previous year's 326.13 million. Losses were -330.30 million, 677.1% more than in 2022.